Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan 5:5:470.
doi: 10.3389/fphys.2014.00470. eCollection 2014.

Encapsulating peritoneal sclerosis-a rare but devastating peritoneal disease

Affiliations
Review

Encapsulating peritoneal sclerosis-a rare but devastating peritoneal disease

Zia Moinuddin et al. Front Physiol. .

Abstract

Encapsulating peritoneal sclerosis (EPS) is a devastating but, fortunately, rare complication of long-term peritoneal dialysis. The disease is associated with extensive thickening and fibrosis of the peritoneum resulting in the formation of a fibrous cocoon encapsulating the bowel leading to intestinal obstruction. The incidence of EPS ranges between 0.7 and 3.3% and increases with duration of peritoneal dialysis therapy. Dialysis fluid is hyperosmotic, hyperglycemic, and acidic causing chronic injury and inflammation in the peritoneum with loss of mesothelium and extensive tissue fibrosis. The pathogenesis of EPS, however, still remains uncertain, although a widely accepted hypothesis is the "two-hit theory," where, the first hit is chronic peritoneal membrane injury from long standing peritoneal dialysis followed by a second hit such as an episode of peritonitis, genetic predisposition and/or acute cessation of peritoneal dialysis, leading to EPS. Recently, EPS has been reported in patients shortly after transplantation suggesting that this procedure may also act as a possible second insult. The process of epithelial-mesenchymal transition of mesothelial cells is proposed to play a central role in the development of peritoneal sclerosis, a common characteristic of patients on dialysis, however, its importance in EPS is less clear. There is no established treatment for EPS although evidence from small case studies suggests that corticosteroids and tamoxifen may be beneficial. Nutritional support is essential and surgical intervention (peritonectomy and enterolysis) is recommended in later stages to relieve bowel obstruction.

Keywords: encapsulating peritoneal sclerosis; epithelial–mesenchymal transition; fibrosis; mesothelium; peritoneal dialysis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Macroscopic appearance of EPS at surgery. (A) Thickened parietal peritoneum is held up by surgical clips. Visceral peritoneum is thickened forming a fibrous cocoon encapsulating the bowel. (B) Visceral peritoneum peeled off the small bowel which has a brownish, tanned leathery appearance.
Figure 2
Figure 2
Proposed pathogenesis of EPS: “Two-hit” theory (Modified from Augustine et al., 2009). AGE, Advanced Glycation End-products; RAGE, Receptors for Advanced Glycation End-products; IL-1, Interleukin-1; TNF, Tumor Necrosis Factor; TGF-β, Transforming Growth Factor-β; VEGF, Vascular Endothelial Growth Factor; EMT, Epithelial to Mesenchymal Transdifferentiation; MMP, Matrix Metalloproteinases; ECM, Extracellular Matrix.

Similar articles

Cited by

References

    1. Aguilera A., Yáñez-Mo M., Selgas R., Sánchez-Madrid F., López-Cabrera M. (2005). Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients. Curr. Opin. Investig. Drugs 6, 262–268. - PubMed
    1. Alscher D. M., Braun N., Biegger D., Fritz P. (2007). Peritoneal mast cells in peritoneal dialysis patients, particularly in encapsulating peritoneal sclerosis patients. Am. J. Kidney Dis. 49, 452–461. 10.1053/j.ajkd.2006.11.040 - DOI - PubMed
    1. Aroeira L. S., Aguilera A., Sánchez-Tomero J. A., Bajo M. A., del Peso G., Jiménez-Heffernan J. A., et al. . (2007). Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J. Am. Soc. Nephrol. 18, 2004–2011. 10.1681/ASN.2006111292 - DOI - PubMed
    1. Augustine T., Brown P. W., Davies S. D., Summers A. M., Wilkie M. E. (2009). Encapsulating peritoneal sclerosis: clinical significance and implications. Nephron. Clin. Pract. 111, 149–154. 10.1159/000191214 - DOI - PubMed
    1. Balasubramaniam G., Brown E. A., Davenport A., Cairns H., Cooper B., Fan S. L., et al. . (2009). The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol. Dial. Transplant. 24, 3209–3215. 10.1093/ndt/gfp008 - DOI - PubMed

LinkOut - more resources